Brief report: Inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis

Arthritis and Rheumatism

Volumn 64, Issue 8, 2012, Pages 2499-2503

  Samson, Maxime ^a,b   Audia, Sylvain ^a,b   Janikashvili, Nona ^a,b   Ciudad, Marion ^a,b   Trad, Malika ^a,b   Fraszczak, Jennifer ^a,b   Ornetti, Paul ^c   Maillefert, Jean Francis ^c   Miossec, Pierre ^d   Bonnotte, Bernard ^a,b  

^a CNRS   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c HÔPITAL DU BOCAGE   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CD4 ANTIGEN; CERTOLIZUMAB PEGOL; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE 28; FEMALE; HUMAN; INFLAMMATION; MALE; PHENOTYPE; PRESCRIPTION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; T LYMPHOCYTE; TH17 CELL;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; CELL COUNT; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PHENOTYPE; RECEPTORS, INTERLEUKIN-6; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84864481289     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34477     Document Type: Article

References (16)

1. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-8.
2. Miossec P,. Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy [review]. Arthritis Rheum 2003; 48: 594-601.
3. Miossec P,. Interleukin-17 in fashion, at last: ten years after its description, its cellular source has been identified [review]. Arthritis Rheum 2007; 56: 2111-5.
4. Boe A, Baiocchi M, Carbonatto M, Papoian R, Serlupi-Crescenzi O,. Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis. Cytokine 1999; 11: 1057-64.
5. Nowell MA, Williams AS, Carty SA, Scheller J, Hayes AJ, Jones GW, et al. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J Immunol 2009; 182: 613-22.
6. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy study. Arthritis Rheum 2008; 58: 2968-80.
7. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371: 987-97.
8. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F,. Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007; 8: 942-9.
9. Cosmi L, De Palma R, Santarlasci V, Maggi L, Capone M, Frosali F, et al. Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J Exp Med 2008; 205: 1903-16.
10. Santarlasci V, Maggi L, Capone M, Frosali F, Querci V, De Palma R, et al. TGF-β indirectly favors the development of human Th17 cells by inhibiting Th1 cells. Eur J Immunol 2009; 39: 207-15.
11. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-81.
12. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
13. Hennessy B, North J, Deru A, Llewellyn-Smith N, Lowdell MW,. Use of Leu3a/3b for the accurate determination of CD4 subsets for measurement of intracellular cytokines. Cytometry 2001; 44: 148-52.
14. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J Exp Med 2004; 200: 277-85.
15. Wang W, Shao S, Jiao Z, Guo M, Xu H, Wang S,. The Th17/Treg imbalance and cytokine environment in peripheral blood of patients with rheumatoid arthritis. Rheumatol Int 2012; 32: 887-93.
16. Peck A, Mellins ED,. Plasticity of T-cell phenotype and function: the T helper type 17 example. Immunology 2010; 129: 147-53.